This research is for continuance of the NSABP Group Operations Office, the Biostatistical Center, and Sub-contract support for non-grant-funded institutional members. The NSABP cooperative trials group was founded in 1958 and since 1970 has been headquartered at the University of Pittsburgh under the aegis of NCI Grant CA-12027, which in 1983 became a cooperative agreement. Included in this application are the elements of U10-CA-34211 and U10-CA-34212. These two cooperative agreements (formerly contracts) have been supporting NSABP breast and colo-rectal patient accrual since 1972 and 1977, respectively. Our long-range goal is to markedly improve the survival of patients with breast and colo-rectal cancers through more efficacious treatment strategies.
Major specific aims for the upcoming five-year project period include: 1) complete accrual of on-going breast (B-13 thru B-17) colon (C- 02) and rectal (R-01) protocols; 2) continue long-term follow-up on all NSABP trials initiated since 1971 that have completed accrual; 3) update and continue follow-up on first generation breast protocols (B-01, B-02, B-03); 4) design and implement successor protocols; 5) initiate a protocol for locally advanced breast cancer; 6) extend quality control procedures to insure the integrity of treatments administered and validity of long-term therapeutic results; 7) continue the study of pathologic parameters; 8) assess tumor cell kinetics and receptors as predictive discriminants; and 9) initiate a male breast cancer registry. The NSABP has developed and implemented standardized methods and procedures across all protocols which include: 1) a thorough eligibility check at randomization of the large numbers of patients accrued through member institutions; 2) centralized review of pathology materials for all patients; 3) careful on-going toxicity monitoring to ensure identification and prevention of potential problems; 4)verification and editing of coded data with built-in quality assurance mechanisms; 5) detailed mechanisms that minimize delinquent data submission and ensure long-term follow-up reporting ; 6) medical audits of all active NSABP institutions at least once each three years; 7) regular reviews of institutional performance with respect to accrual compliance with protocol and data requirements and overall participation; 8) maintenance of appropriate administrative and fiscal records for institutions supported by subcontract; and 9) presentation of status for all protocols at semi-annual NSABP group meetings with publication of results in the literature.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA012027-18
Application #
3556034
Study Section
(SRC)
Project Start
1976-12-01
Project End
1992-01-31
Budget Start
1989-02-01
Budget End
1990-01-31
Support Year
18
Fiscal Year
1989
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Regan, M M; Walley, B A; Francis, P A et al. (2017) Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Ann Oncol 28:2225-2232
Ternès, Nils; Rotolo, Federico; Michiels, Stefan (2017) Robust estimation of the expected survival probabilities from high-dimensional Cox models with biomarker-by-treatment interactions in randomized clinical trials. BMC Med Res Methodol 17:83
Saha, Poornima; Regan, Meredith M; Pagani, Olivia et al. (2017) Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. J Clin Oncol 35:3113-3122
Ribi, Karin; Bernhard, Jürg; Luo, Weixiu et al. (2016) Reply to F. Tomao et al. J Clin Oncol 34:4189-4190
Regan, Meredith M; Francis, Prudence A; Pagani, Olivia et al. (2016) Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. J Clin Oncol 34:2221-31
Cheung, Winson Y; Renfro, Lindsay A; Kerr, David et al. (2016) Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. J Clin Oncol 34:1182-9
Phillips, Kelly-Anne; Regan, Meredith M; Ribi, Karin et al. (2016) Adjuvant ovarian function suppression and cognitive function in women with breast cancer. Br J Cancer 114:956-64
Christian, Nicholas J; Ha, Il Do; Jeong, Jong-Hyeon (2016) Hierarchical likelihood inference on clustered competing risks data. Stat Med 35:251-67
Ribi, Karin; Luo, Weixiu; Bernhard, Jürg et al. (2016) Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol 34:1601-10
Johansson, Harriet; Gray, Kathryn P; Pagani, Olivia et al. (2016) Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. Breast Cancer Res 18:110

Showing the most recent 10 out of 264 publications